HPS
MCID: HNT002
MIFTS: 50

Hantavirus Pulmonary Syndrome (HPS)

Categories: Infectious diseases, Nephrological diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Hantavirus Pulmonary Syndrome

MalaCards integrated aliases for Hantavirus Pulmonary Syndrome:

Name: Hantavirus Pulmonary Syndrome 12 52 58 29 3 43 15 17 71
Hps 52 3
Hantavirus-Associated Respiratory Distress Syndrome 52
Four Corners Hantavirus 52
Hanta Virus 71
Hantavirus 52
Hards 52

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:14472
MeSH 43 D018804
NCIt 49 C84747
SNOMED-CT 67 120639003
ICD10 32 B33.4
ICD10 via Orphanet 33 B33.4+ J17.1*
UMLS via Orphanet 72 C0243025
Orphanet 58 ORPHA319247
UMLS 71 C0243025 C0854421

Summaries for Hantavirus Pulmonary Syndrome

Disease Ontology : 12 A viral infectious disease that results in infection located in lung, has material basis in Sin Nombre virus, transmitted by deer mouse (Myodes glareolus), has material basis in Black Creek Canal virus, transmitted by cotton rat (Sigmodon hispidus), has material basis in Bayou virus, transmitted by marsh rice rat (Oryzomys palustris), has material basis in Laguna Negra virus, transmitted by small vesper mouse (Calomys laucha), or has material basis in Andes virus, transmitted by rice rat (Oligoryzomys longicaudatus). The infection has symptom fever, has symptom muscle pain, has symptom headache, has symptom cough, has symptom vomiting, has symptom chills which rapidly progress to bilateral interstitial pulmonary infiltrates occurrence, pulmonary edema and hypoxia often resulting in death from shock or cardiac complications.

MalaCards based summary : Hantavirus Pulmonary Syndrome, also known as hps, is related to viral pneumonia and respiratory failure. An important gene associated with Hantavirus Pulmonary Syndrome is F3 (Coagulation Factor III, Tissue Factor), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Human cytomegalovirus infection. The drugs Prednisolone phosphate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include lung, endothelial and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

NIH Rare Diseases : 52 Hantavirus pulmonary syndrome (HPS) is a severe, respiratory disease caused by infection with a hantavirus. People can become infected with a hantavirus through contact with hantavirus-infected rodents or their saliva, urine and/or droppings. Early symptoms universally include fatigue, fever and muscle aches (especially in the thighs, hips, and/or back), and sometimes include headaches, dizziness, chills, and abdominal problems such as nausea, vomiting, diarrhea, and pain. Later symptoms of the syndrome occur 4 to 10 days after initial onset and include coughing and shortness of breath. HPS can be fatal; approximately 38% of individuals with HPS do not survive. There is no cure or specific treatment for HPS, but early diagnosis and treatment in intensive care may increase the chance of recovery.

CDC : 3 Hantaviruses are a family of viruses spread mainly by rodents and can cause varied disease syndromes in people worldwide. Infection with any hantavirus can produce hantavirus disease in people. Hantaviruses in the Americas are known as "New World" hantaviruses and may cause hantavirus pulmonary syndrome (HPS). Other hantaviruses, known as "Old World" hantaviruses, are found mostly in Europe and Asia and may cause hemorrhagic fever with renal syndrome (HFRS). Each hantavirus serotype has a specific rodent host species and is spread to people via aerosolized virus that is shed in urine, feces, and saliva, and less frequently by a bite from an infected host. The most important hantavirus in the United States that can cause HPS is the Sin Nombre virus, spread by the deer mouse.

Wikipedia : 74 Hantavirus pulmonary syndrome (HPS) is one of two potentially fatal syndromes of zoonotic origin caused... more...

Related Diseases for Hantavirus Pulmonary Syndrome

Diseases related to Hantavirus Pulmonary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 1489, show less)
# Related Disease Score Top Affiliating Genes
1 viral pneumonia 32.3 IFNB1 CD8A CD40LG
2 respiratory failure 31.0 LTA F3 F2 CD40LG
3 hemopericardium 30.8 F3 F2
4 anuria 30.7 F3 F2 CD40LG
5 syphilis 30.7 F2 CD8A CD40LG
6 leptospirosis 30.6 IL1A F2 CD40LG
7 acalculous cholecystitis 30.6 F2 CD40LG
8 leukemia, chronic lymphocytic 30.4 VEGFA SYK LYN LTA CD8A CD40LG
9 hemorrhagic disease 30.4 F3 F2 CD40LG
10 antiphospholipid syndrome 30.4 F3 F2 CD40LG
11 danubian endemic familial nephropathy 30.4 UBASH3A F2 CD40LG
12 kaposi sarcoma 30.3 VEGFA KDR IRF3 IFNB1
13 toxic shock syndrome 30.3 LTA F3 CD40LG
14 yellow fever 30.3 LTA IL1A IFNB1
15 purpura 30.2 F3 F2 CD40LG
16 thrombocytosis 30.2 IL1A F3 F2
17 hemolytic-uremic syndrome 30.2 F3 F2 CD40LG
18 thrombocytopenia due to platelet alloimmunization 30.2 SYK CD8A CD40LG
19 pulmonary embolism 30.1 F3 F2 CD40LG
20 cavernous sinus thrombosis 30.1 F3 F2
21 aspiration pneumonia 30.1 F3 F2 CD40LG
22 heparin-induced thrombocytopenia 30.1 F3 CD40LG
23 pericardial effusion 30.1 VEGFA F3 F2 CD40LG
24 mediastinitis 30.0 F3 F2
25 bilirubin metabolic disorder 30.0 F3 F2 CD40LG
26 placenta disease 30.0 VEGFA F3 F2
27 hantavirus hemorrhagic fever with renal syndrome 30.0 VEGFA UBASH3A F3 CDH5 CD8A CD40LG
28 dengue disease 29.9 IFNB1 CD8A CD40LG
29 chorioretinitis 29.9 VEGFA CD8A CD40LG
30 cholangitis 29.9 F3 F2 CD40LG
31 thrombocytopenia 29.9 SYK LTA IL1A IFNB1 F3 F2
32 venous insufficiency 29.9 VEGFA IL1A F2
33 dermatitis, atopic 29.8 SYK LTA IL1A CD8A
34 sarcoidosis 1 29.8 LTA IL1A CD8A CD40LG
35 ovarian hyperstimulation syndrome 29.7 VEGFA KDR CDH5
36 macular retinal edema 29.7 VEGFA KDR IFNB1
37 autoimmune disease 29.7 SYK LTA IL1A IFNB1 CD40LG
38 lassa fever 29.6 IRF3 CD8A CD40LG
39 mantle cell lymphoma 29.6 VEGFA SYK LYN CD40LG
40 secondary syphilis 29.6 CD8A CD40LG
41 central retinal vein occlusion 29.6 VEGFA F3 F2
42 schistosomiasis 29.6 VEGFA IL1A F2 CD40LG
43 dengue hemorrhagic fever 29.5 VEGFA IFNB1 F3 F2 CD40LG
44 chickenpox 29.5 IFNB1 CD8A CD40LG
45 cholangitis, primary sclerosing 29.4 F2 CD8A CD40LG
46 microvascular complications of diabetes 5 29.4 VEGFA KDR CDH5
47 pneumonia 29.4 IL1A IFNB1 F3 F2 CD8A CD40LG
48 lung disease 29.3 VEGFA IL1A F3 CD8A CD40LG
49 bone inflammation disease 29.3 VEGFA IL1A CD8A CD40LG
50 lymphoma, non-hodgkin, familial 29.3 VEGFA SYK LYN CD8A CD40LG
51 peripheral vascular disease 29.3 VEGFA F3 F2
52 papilledema 29.3 VEGFA F3 F2 CD40LG
53 hemangioma 29.3 VEGFA KDR F3 F2
54 progressive multifocal leukoencephalopathy 29.3 IFNB1 CD8A CD40LG
55 corneal disease 29.2 VEGFA IL1A CD8A
56 listeriosis 29.1 IRF3 IFNB1 CD8A
57 limb ischemia 29.1 VEGFA KDR F2
58 peripheral nervous system disease 29.1 VEGFA IFNB1 CD8A CD40LG
59 lipoprotein quantitative trait locus 29.0 VEGFA KDR F3 F2 CD40LG
60 severe acute respiratory syndrome 29.0 IRF3 IFNB1 CD40LG
61 bacterial infectious disease 29.0 IRF3 IL1A IFNB1 CD8A CD40LG
62 systemic lupus erythematosus 28.9 VEGFA SYK LYN LTA IRF3 IL1A
63 parasitic protozoa infectious disease 28.9 KDR CD8A CD40LG
64 corneal neovascularization 28.8 VEGFA ROBO4 KDR
65 retinal vein occlusion 28.7 VEGFA KDR F3 F2 CD40LG
66 retinal vascular disease 28.7 VEGFA KDR CDH5
67 optic nerve disease 28.7 VEGFA IFNB1 CD8A CD40LG
68 vascular disease 28.6 VEGFA KDR IL1A F3 F2 CD40LG
69 rheumatoid arthritis 28.6 VEGFA SYK LTA IL1A IFNB1 CD40LG
70 exanthem 28.5 VEGFA KDR F3 F2 CD8A CD40LG
71 myelofibrosis 28.5 VEGFA LYN KDR CD40LG
72 portal hypertension 28.4 VEGFA KDR F3 F2 CD40LG
73 pre-eclampsia 28.3 VEGFA KDR F3 F2 CD40LG
74 malaria 28.3 VEGFA LTA IL1A IFNB1 F3 F2
75 heart disease 28.3 VEGFA KDR IFNB1 F3 F2 CD40LG
76 eye disease 28.2 VEGFA KDR IL1A CD8A CD40LG
77 inflammatory bowel disease 28.0 VEGFA LTA IL1A IFNB1 F3 F2
78 diabetes mellitus 28.0 VEGFA LTA KDR IL1A F3 F2
79 myocardial infarction 27.9 VEGFA LTA KDR IL1A F3 F2
80 exudative vitreoretinopathy 1 27.8 VEGFA KDR CDH5
81 hypertension, essential 27.2 VEGFA KDR IL1A F3 F2 CDH5
82 parana hard-skin syndrome 12.6
83 hard palate cancer 12.6
84 cleft hard palate 12.5
85 teeth hard tissue disease 12.4
86 hermansky-pudlak syndrome 12.3
87 winter harding hyde syndrome 12.3
88 walker-warburg syndrome 12.1
89 pancreatitis, hereditary 11.9
90 cerebellar ataxia, early-onset, with retained tendon reflexes 11.9
91 muscular dystrophy-dystroglycanopathy , type a, 1 11.8
92 hepatopulmonary syndrome 11.7
93 cleft palate, isolated 11.7
94 hermansky-pudlak syndrome 1 11.6
95 hermansky-pudlak syndrome 5 11.6
96 stiff skin syndrome 11.6
97 hermansky-pudlak syndrome with pulmonary fibrosis 11.5
98 hermansky-pudlak syndrome 2 11.5
99 tooth disease 11.5
100 pertussis 11.5
101 constipation 11.4
102 hermansky-pudlak syndrome 3 11.4
103 hermansky-pudlak syndrome 4 11.4
104 hermansky-pudlak syndrome 6 11.4
105 hermansky-pudlak syndrome 7 11.4
106 systemic scleroderma 11.4
107 lyme disease 11.4
108 nephrolithiasis, calcium oxalate 11.4
109 pancreatic cancer 11.4
110 gastric cancer 11.3
111 pulmonary hypertension 11.3
112 priapism 11.3
113 ovarian cancer 11.3
114 pulmonary disease, chronic obstructive 11.3
115 leukemia 11.3
116 endosteal hyperostosis, autosomal dominant 11.3
117 fibromyalgia 11.3
118 pulmonary fibrosis 11.3
119 dental caries 11.3
120 interstitial lung disease 11.3
121 autism spectrum disorder 11.2
122 disease of mental health 11.2
123 necrotizing sialometaplasia 11.2
124 odontoma 11.2
125 psoriasis 11.2
126 head injury 11.2
127 familial adenomatous polyposis 1 11.2
128 laryngoonychocutaneous syndrome 11.2
129 macular degeneration, age-related, 1 11.2
130 anxiety 11.2
131 leukemia, acute lymphoblastic 11.2
132 attention deficit-hyperactivity disorder 11.2
133 schizophrenia 11.2
134 hermansky-pudlak syndrome without pulmonary fibrosis 11.2
135 hemiparkinsonism-hemiatrophy syndrome 11.2
136 pilomatrixoma 11.2
137 esophageal cancer 11.2
138 leukemia, acute myeloid 11.2
139 leukemia, chronic myeloid 11.2
140 leukoplakia 11.2
141 usher syndrome, type i 11.2
142 juvenile arthritis 11.2
143 amblyopia 11.2
144 localized scleroderma 11.2
145 sickle cell disease 11.2
146 swallowing disorders 11.2
147 obsessive-compulsive disorder 11.2
148 parkinson disease, late-onset 11.2
149 myasthenia gravis 11.2
150 dermatofibrosarcoma protuberans 11.2
151 fetal alcohol syndrome 11.2
152 aphasia 11.2
153 stuttering 11.2
154 charcot-marie-tooth disease 11.2
155 spinal muscular atrophy 11.2
156 gout 11.2
157 porphyria 11.2
158 neuroendocrine tumor 11.2
159 epidermolysis bullosa 11.2
160 congenital hepatic fibrosis 11.2
161 diabetic mastopathy 11.2
162 hypersensitivity pneumonitis, familial 11.1
163 hermansky-pudlak syndrome 8 11.1
164 hermansky-pudlak syndrome 9 11.1
165 hermansky-pudlak syndrome 10 11.1
166 hyperprolinemia 11.1
167 cleft lip/palate 11.1
168 dupuytren contracture 11.0
169 keratitis-ichthyosis-deafness syndrome, autosomal dominant 11.0
170 melkersson-rosenthal syndrome 11.0
171 spinocerebellar ataxia 1 11.0
172 gnathodiaphyseal dysplasia 11.0
173 ichthyosis, congenital, autosomal recessive 4b 11.0
174 amelogenesis imperfecta, type ie 11.0
175 orthostatic intolerance 11.0
176 restless legs syndrome 11.0
177 kyasanur forest disease 11.0
178 von willebrand's disease 11.0
179 hidradenitis suppurativa 11.0
180 gallbladder cancer 11.0
181 brittle diabetes 11.0
182 cardiofaciocutaneous syndrome 1 10.9
183 darier-white disease 10.9
184 dementia, lewy body 10.9
185 gilles de la tourette syndrome 10.9
186 gilbert syndrome 10.9
187 palmoplantar keratoderma, punctate type ia 10.9
188 klippel-trenaunay-weber syndrome 10.9
189 neuropathy, hereditary, with liability to pressure palsies 10.9
190 spinocerebellar ataxia 7 10.9
191 nail disorder, nonsyndromic congenital, 5 10.9
192 buschke-ollendorff syndrome 10.9
193 pemphigus vulgaris, familial 10.9
194 mccune-albright syndrome 10.9
195 spinocerebellar ataxia 2 10.9
196 blau syndrome 10.9
197 torus palatinus and torus mandibularis 10.9
198 trigeminal neuralgia 10.9
199 trigger thumb 10.9
200 agenesis of the corpus callosum with peripheral neuropathy 10.9
201 deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures syndrome 10.9
202 fascial dystrophy, congenital 10.9
203 glutaric acidemia i 10.9
204 glutathionuria 10.9
205 stargardt disease 1 10.9
206 mal de meleda 10.9
207 hyperoxaluria, primary, type ii 10.9
208 d-bifunctional protein deficiency 10.9
209 schinzel-giedion midface retraction syndrome 10.9
210 restrictive dermopathy, lethal 10.9
211 usher syndrome, type ic 10.9
212 cleft palate with or without ankyloglossia, x-linked 10.9
213 aicardi syndrome 10.9
214 focal dermal hypoplasia 10.9
215 spinal and bulbar muscular atrophy, x-linked 1 10.9
216 pearson marrow-pancreas syndrome 10.9
217 usher syndrome, type id 10.9
218 cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss 10.9
219 spinocerebellar ataxia 10 10.9
220 phelan-mcdermid syndrome 10.9
221 spinocerebellar ataxia 15 10.9
222 crigler-najjar syndrome, type ii 10.9
223 spinal muscular atrophy, distal, autosomal recessive, 3 10.9
224 chromosome 3q29 duplication syndrome 10.9
225 microtia, hearing impairment, and cleft palate 10.9
226 usher syndrome, type ih 10.9
227 alpha-1-antitrypsin deficiency 10.9
228 usher syndrome, type ij 10.9
229 usher syndrome, type ik 10.9
230 ring chromosome 14 syndrome 10.9
231 cleft palate, psychomotor retardation, and distinctive facial features 10.9
232 microcephaly 17, primary, autosomal recessive 10.9
233 amelogenesis imperfecta, type ij 10.9
234 hirata disease 10.9
235 asperger syndrome 10.9
236 early infantile epileptic encephalopathy 10.9
237 oromandibular dystonia 10.9
238 achondrogenesis 10.9
239 dermatomyositis 10.9
240 yaws 10.9
241 leukodystrophy 10.9
242 obsessive-compulsive personality disorder 10.9
243 cat-scratch disease 10.9
244 megacolon 10.9
245 prediabetes syndrome 10.9
246 bronchial disease 10.9
247 conjunctival concretion 10.9
248 cartilage disease 10.9
249 black piedra 10.9
250 hereditary spherocytosis 10.9
251 congenital dyserythropoietic anemia 10.9
252 osteopetrosis 10.9
253 islet cell tumor 10.9
254 bursitis 10.9
255 primary hyperoxaluria 10.9
256 scirrhous adenocarcinoma 10.9
257 mouth disease 10.9
258 nutritional deficiency disease 10.9
259 dentin dysplasia 10.9
260 breast scirrhous carcinoma 10.9
261 childhood leukemia 10.9
262 chronic fatigue syndrome 10.9
263 penis carcinoma in situ 10.9
264 hemorrhoid 10.9
265 acquired angioedema 10.9
266 chromosome 20p duplication 10.9
267 hemimegalencephaly 10.9
268 idiopathic hypersomnia 10.9
269 ledderhose disease 10.9
270 myelodysplastic syndrome with excess blasts 10.9
271 prosthetic joint infection 10.9
272 prurigo nodularis 10.9
273 vernal keratoconjunctivitis 10.9
274 naegeli-franceschetti-jadassohn syndrome/dermatopathia pigmentosa reticularis 10.9
275 familial pityriasis rubra pilaris 10.9
276 cumulative trauma disorders 10.9
277 lyme disease - neurological complications 10.9
278 ohtahara syndrome 10.9
279 overuse syndrome 10.9
280 repetitive motion disorders 10.9
281 repetitive stress injuries 10.9
282 warty dyskeratoma 10.9
283 pulmonary edema 10.7
284 acute kidney failure 10.6
285 tooth erosion 10.6
286 korean hemorrhagic fever 10.6
287 achenbach syndrome 10.6 F3 F2
288 synovial angioma 10.5 F3 F2
289 renal pelvis squamous cell carcinoma 10.5 F3 F2
290 papillary adenofibroma 10.5 F3 F2
291 blue toe syndrome 10.5 F3 F2
292 emphysematous cholecystitis 10.5 F3 F2
293 femoral neuropathy 10.5 F3 F2
294 lateral sinus thrombosis 10.5 F3 F2
295 giant hemangioma 10.5 F3 F2
296 dic in newborn 10.5 F3 F2
297 waterhouse-friderichsen syndrome 10.5 F3 F2
298 hemopneumothorax 10.5 F3 F2
299 lemierre's syndrome 10.5 F3 F2
300 cataract 10.5
301 hair whorl 10.5
302 gastric hemangioma 10.5 F3 F2
303 hepatic infarction 10.5 F3 F2
304 kidney disease 10.5
305 retroperitoneal lymphoma 10.5 F2 CD40LG
306 qualitative platelet defect 10.5 F3 F2
307 astrakhan spotted fever 10.5 F3 CD40LG
308 cleft lip with or without cleft palate 10.5
309 ankylosing spondylitis 1 10.5 F3 F2
310 marantic endocarditis 10.5 F3 F2
311 cleft lip 10.5
312 intracranial sinus thrombosis 10.5 F3 F2
313 epidural abscess 10.5 F3 F2
314 cerebral sinovenous thrombosis 10.5 F3 F2
315 catastrophic antiphospholipid syndrome 10.5 F3 CD40LG
316 adult respiratory distress syndrome 10.4
317 prothrombin deficiency 10.4 F3 F2
318 splenic abscess 10.4 F2 CD40LG
319 alkhurma hemorrhagic fever 10.4 F3 CD40LG
320 helicobacter pylori infection 10.4
321 sagittal sinus thrombosis 10.4 F3 F2
322 fournier gangrene 10.4 F3 F2 CD40LG
323 splenic infarction 10.4 F3 F2 CD40LG
324 splenic sequestration 10.4 F3 F2 CD40LG
325 cork-handlers' disease 10.4 CD8A CD40LG
326 thrombophlebitis 10.4 F3 F2 CD40LG
327 autoimmune disease of cardiovascular system 10.4 F3 F2 CD40LG
328 branchiootic syndrome 1 10.4
329 post-transplant lymphoproliferative disease 10.3 LTA IL1A
330 endocardium disease 10.3 F3 F2 CD40LG
331 permanent molars, secondary retention of 10.3
332 pneumoconiosis 10.3
333 anthracosis 10.3
334 interstitial nephritis 10.3
335 bone resorption disease 10.3
336 impotence 10.3
337 early yaws 10.3 CD8A CD40LG
338 cerebral falx meningioma 10.3 F3 F2
339 melanoma, cutaneous malignant 10 10.3
340 melanoma 10.3
341 takayasu arteritis 10.3 F3 F2 CD40LG
342 norwegian scabies 10.3 CD8A CD40LG
343 dysphagia 10.3
344 agammaglobulinemia, x-linked 10.3 SYK LYN CD40LG
345 rapidly involuting congenital hemangioma 10.3
346 intracranial hypotension 10.3 F3 F2
347 adenoma 10.3
348 intracranial embolism 10.3 F3 F2
349 viral exanthem 10.3 CD8A CD40LG
350 tertiary syphilis 10.3 CD8A CD40LG
351 acute retinal necrosis syndrome 10.3 CD8A CD40LG
352 dermatitis 10.3
353 diabetic macular edema 10.3
354 joint laxity, short stature, and myopia 10.3
355 myopia 10.3
356 lymphocytic choriomeningitis 10.3
357 chronic kidney disease 10.3
358 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
359 cardiogenic shock 10.3
360 osteosclerotic myeloma 10.2 VEGFA CD40LG
361 transient hypogammaglobulinemia 10.2 LTA CD40LG
362 cerebritis 10.2 CD8A CD40LG
363 granulomatous hepatitis 10.2 CD8A CD40LG
364 melioidosis 10.2
365 respiratory syncytial virus infectious disease 10.2
366 chronic interstitial cystitis 10.2
367 human immunodeficiency virus type 1 10.2
368 pleomorphic adenoma 10.2
369 albinism 10.2
370 autoimmune disease of blood 10.2 F3 CD8A CD40LG
371 plasma protein metabolism disease 10.2 F2 CD8A CD40LG
372 squamous cell carcinoma 10.2
373 bacillary angiomatosis 10.2 VEGFA CD40LG
374 tooth ankylosis 10.2
375 hypercementosis 10.2
376 tooth resorption 10.2
377 external pathological resorption 10.2
378 capillary leak syndrome 10.2
379 myocarditis 10.2
380 viral hemorrhagic fever 10.2
381 autoimmune disease of gastrointestinal tract 10.2 F2 CD8A CD40LG
382 disseminated intravascular coagulation 10.2
383 guillain-barre syndrome 10.2
384 glomerulonephritis 10.2
385 end stage renal disease 10.2
386 stomatitis 10.2
387 headache 10.2
388 opportunistic mycosis 10.2 SYK CD8A CD40LG
389 lymphoma 10.2
390 west nile encephalitis 10.2 CD8A CD40LG
391 fungal infectious disease 10.2 SYK CD8A CD40LG
392 cryptosporidiosis 10.2 IL1A CD8A CD40LG
393 autism 10.2
394 aging 10.2
395 periodontitis 10.2
396 nephrosclerosis 10.2 VEGFA F3 F2
397 hypertensive encephalopathy 10.2 VEGFA F2
398 moyamoya disease 1 10.2 VEGFA F3 F2
399 typhoid fever 10.1 LTA IL1A F2 CD40LG
400 oculocutaneous albinism 10.1
401 urethral stricture 10.1
402 cecal disease 10.1 UBASH3A F3 F2 CD40LG
403 chorioretinal scar 10.1 VEGFA CD40LG
404 breast cancer 10.1
405 immunoglobulin switch sequences 10.1
406 tick-borne encephalitis 10.1
407 epidemic typhus 10.1
408 scrub typhus 10.1
409 hypopituitarism 10.1
410 central retinal artery occlusion 10.1 VEGFA F2 CD40LG
411 branch retinal artery occlusion 10.1 VEGFA F2
412 fibrosis of extraocular muscles, congenital, 1 10.1
413 astigmatism 10.1
414 adenoid cystic carcinoma 10.1
415 sarcoma 10.1
416 neurilemmoma 10.1
417 spindle cell sarcoma 10.1
418 listeria meningitis 10.1 IFNB1 CD8A
419 intermittent claudication 10.1 VEGFA F2 CD40LG
420 gastric adenocarcinoma 10.1
421 papilloma 10.1
422 substance abuse 10.1
423 tick infestation 10.1
424 aneurysm 10.1
425 hepatitis e 10.1 IFNB1 F2 CD40LG
426 plague 10.1
427 lactic acidosis 10.1
428 cytokine deficiency 10.1
429 x-linked recessive disease 10.1 F3 CD8A CD40LG
430 squamous cell papilloma 10.1
431 acute chest syndrome 10.1 VEGFA IL1A CD40LG
432 meningoencephalitis 10.1
433 crimean-congo hemorrhagic fever 10.1
434 acute kidney tubular necrosis 10.1
435 rift valley fever 10.1
436 coccidioidomycosis 10.1
437 48,xyyy 10.1
438 ptosis 10.1
439 keratoconus 10.1
440 nephrolithiasis 10.1
441 pik3ca-related overgrowth syndrome 10.1
442 acute hemorrhagic encephalitis 10.1 F3 F2 CD8A CD40LG
443 primary thrombocytopenia 10.1 F3 F2 CD8A CD40LG
444 pericardium disease 10.1 F3 F2 CD8A CD40LG
445 splenic disease 10.1 F3 F2 CD8A CD40LG
446 keratitis, hereditary 10.0
447 osteogenic sarcoma 10.0
448 sleep apnea 10.0
449 silicosis 10.0
450 relapsing fever 10.0
451 b-cell lymphoma 10.0
452 osteoarthritis 10.0
453 alcohol dependence 10.0
454 atherosclerosis susceptibility 10.0
455 yemenite deaf-blind hypopigmentation syndrome 10.0
456 coronary heart disease 1 10.0
457 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.0
458 chronic ulcer of skin 10.0
459 pneumothorax 10.0
460 mucoepidermoid carcinoma 10.0
461 extrinsic allergic alveolitis 10.0
462 learning disability 10.0
463 parotid disease 10.0 CD8A CD40LG
464 dowling-degos disease 1 10.0
465 scleroderma, familial progressive 10.0
466 arts syndrome 10.0
467 fibroma 10.0
468 urolithiasis 10.0
469 osteomyelitis 10.0
470 gingival recession 10.0
471 entropion 10.0
472 contact dermatitis 10.0
473 lipid metabolism disorder 10.0
474 oral cancer 10.0
475 anhaptoglobinemia 10.0
476 gastric lymphoma 10.0
477 neuroblastoma 10.0
478 virus associated hemophagocytic syndrome 10.0
479 hemophagocytic syndrome associated with an infection 10.0
480 pleural disease 10.0 VEGFA F2 CD8A
481 pituitary hormone deficiency, combined, 2 10.0
482 helix syndrome 10.0
483 metabolic acidosis 10.0
484 nephrotic syndrome 10.0
485 diarrhea 10.0
486 acute closed-angle glaucoma 10.0
487 dumping syndrome 10.0
488 hypothyroidism 10.0
489 viral hepatitis 10.0
490 cholecystitis 10.0
491 membranoproliferative glomerulonephritis 10.0
492 arthropathy 10.0
493 severe combined immunodeficiency 10.0
494 appendicitis 10.0
495 diabetes insipidus 10.0
496 babesiosis 10.0
497 splenomegaly 10.0
498 overgrowth syndrome 10.0
499 fallopian tube disease 10.0 VEGFA CD8A CD40LG
500 autoimmune disease of peripheral nervous system 10.0 IFNB1 CD8A CD40LG
501 pulmonary artery disease 10.0 VEGFA F3 F2 CD40LG
502 hepatic vascular disease 10.0 VEGFA F3 F2 CD40LG
503 blood protein disease 10.0 VEGFA F3 F2 CD40LG
504 lipomatosis, multiple 10.0
505 retinal detachment 10.0
506 asthma 10.0
507 hyperlipoproteinemia, type iii 10.0
508 pleomorphic lipoma 10.0
509 myoepithelioma 10.0
510 adenocarcinoma 10.0
511 gingivitis 10.0
512 skin disease 10.0
513 conjunctivitis 10.0
514 myeloid leukemia 10.0
515 chronic pain 10.0
516 posttransplant acute limbic encephalitis 10.0
517 hellp syndrome 10.0 VEGFA F3 F2 CD40LG
518 spinal cord disease 10.0 IFNB1 CD8A CD40LG
519 essential thrombocythemia 10.0 VEGFA F3 F2 CD40LG
520 extrinsic cardiomyopathy 10.0 IFNB1 CD8A CD40LG
521 myositis 9.9
522 triiodothyronine receptor auxiliary protein 9.9
523 ventricular fibrillation, paroxysmal familial, 1 9.9
524 dengue virus 9.9
525 cardiac arrest 9.9
526 neuroretinitis 9.9
527 pyelonephritis 9.9
528 neutropenia 9.9
529 gastroenteritis 9.9
530 acute interstitial pneumonia 9.9
531 acute pancreatitis 9.9
532 vaccinia 9.9
533 retinitis 9.9
534 viral infectious disease 9.9
535 encephalitis 9.9
536 toxoplasmosis 9.9
537 47,xyy 9.9
538 ocular toxoplasmosis 9.9
539 anoxia 9.9
540 hemorrhagic fever-renal syndrome 9.9
541 argyria 9.9
542 uveal disease 9.9 VEGFA CD8A CD40LG
543 arteries, anomalies of 9.9
544 down syndrome 9.9
545 lymphoma, hodgkin, classic 9.9
546 diffuse large b-cell lymphoma 9.9
547 covid-19 9.9
548 root caries 9.9
549 basal cell carcinoma 9.9
550 teratoma 9.9
551 pustulosis of palm and sole 9.9
552 liver cirrhosis 9.9
553 acute stress disorder 9.9
554 cocaine abuse 9.9
555 lupus erythematosus 9.9
556 refractive error 9.9
557 alopecia 9.9
558 depression 9.9
559 hair disease 9.9 VEGFA CD8A CD40LG
560 storage pool platelet disease 9.9
561 sickle cell anemia 9.9
562 t-cell lymphoma, subcutaneous panniculitis-like 9.9
563 endometritis 9.9
564 microinvasive gastric cancer 9.9
565 schizotypal personality disorder 9.9
566 pyloric stenosis 9.9
567 choriocarcinoma 9.9
568 syncope 9.9
569 secondary hemophagocytic lymphohistiocytosis 9.9
570 psoriatic arthritis 9.9 VEGFA LTA IL1A CD40LG
571 colorectal cancer 9.9
572 hepatocellular carcinoma 9.9
573 osteoporosis 9.9
574 cervical cancer 9.9
575 meningioma, radiation-induced 9.9
576 meningioma, familial 9.9
577 bone mineral density quantitative trait locus 8 9.9
578 bone mineral density quantitative trait locus 15 9.9
579 dentin caries 9.9
580 mastitis 9.9
581 hydrocephalus 9.9
582 spinal meningioma 9.9
583 cicatricial entropion 9.9
584 hyperparathyroidism 9.9
585 root resorption 9.9
586 keratosis 9.9
587 post-traumatic stress disorder 9.9
588 giant papillary conjunctivitis 9.9
589 papillary conjunctivitis 9.9
590 enamel erosion 9.9
591 ischemia 9.9
592 dentinogenesis imperfecta 9.9
593 secretory meningioma 9.9
594 lymphoplasmacyte-rich meningioma 9.9
595 compartment syndrome 9.9
596 measles 9.9
597 eating disorder 9.9
598 hypereosinophilic syndrome 9.9
599 soft tissue sarcoma 9.9
600 facial cleft 9.9
601 primary bacterial infectious disease 9.9 IFNB1 CD8A CD40LG
602 cardiac conduction defect 9.9
603 lymphoma, mucosa-associated lymphoid type 9.9
604 ige responsiveness, atopic 9.9
605 otitis media 9.9
606 prostate cancer 9.9
607 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.9
608 hutterite cerebroosteonephrodysplasia syndrome 9.9
609 body mass index quantitative trait locus 11 9.9
610 body mass index quantitative trait locus 9 9.9
611 body mass index quantitative trait locus 8 9.9
612 body mass index quantitative trait locus 1 9.9
613 body mass index quantitative trait locus 4 9.9
614 body mass index quantitative trait locus 10 9.9
615 mycobacterium tuberculosis 1 9.9
616 body mass index quantitative trait locus 7 9.9
617 severe cutaneous adverse reaction 9.9
618 major affective disorder 8 9.9
619 body mass index quantitative trait locus 12 9.9
620 major affective disorder 9 9.9
621 body mass index quantitative trait locus 14 9.9
622 microvascular complications of diabetes 3 9.9
623 microvascular complications of diabetes 4 9.9
624 microvascular complications of diabetes 6 9.9
625 microvascular complications of diabetes 7 9.9
626 body mass index quantitative trait locus 18 9.9
627 body mass index quantitative trait locus 19 9.9
628 body mass index quantitative trait locus 20 9.9
629 erythema multiforme 9.9
630 oral squamous cell carcinoma 9.9
631 follicular lymphoma 9.9
632 salivary gland carcinoma 9.9
633 pervasive developmental disorder 9.9
634 atrial fibrillation 9.9
635 tetanus 9.9
636 dental pulp necrosis 9.9
637 tick-borne relapsing fever 9.9
638 mature cataract 9.9
639 alcohol use disorder 9.9
640 hepatitis c 9.9
641 rectum cancer 9.9
642 exostosis 9.9
643 enamel caries 9.9
644 bronchiolitis 9.9
645 bipolar disorder 9.9
646 aortic aneurysm 9.9
647 liver disease 9.9
648 myoepithelial carcinoma 9.9
649 arthritis 9.9
650 mucormycosis 9.9
651 subacute delirium 9.9
652 acute myocardial infarction 9.9
653 senile cataract 9.9
654 diabetic neuropathy 9.9
655 muscular dystrophy 9.9
656 polymorphous low-grade adenocarcinoma 9.9
657 traumatic brain injury 9.9
658 erythema multiforme major 9.9
659 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.9
660 secondary progressive multiple sclerosis 9.8 VEGFA IFNB1 CD40LG
661 ebola hemorrhagic fever 9.8 IFNB1 F3 CD8A CD40LG
662 diabetes insipidus, nephrogenic, autosomal 9.8
663 erythermalgia, primary 9.8
664 polykaryocytosis inducer 9.8
665 ataxia and polyneuropathy, adult-onset 9.8
666 west nile virus 9.8
667 intraocular pressure quantitative trait locus 9.8
668 retinitis pigmentosa 40 9.8
669 analbuminemia 9.8
670 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
671 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.8
672 chlamydia pneumonia 9.8
673 chikungunya 9.8
674 rocky mountain spotted fever 9.8
675 argentine hemorrhagic fever 9.8
676 interleukin-7 receptor alpha deficiency 9.8
677 purpura fulminans 9.8
678 sensorineural hearing loss 9.8
679 viral meningitis 9.8
680 renal hypertension 9.8
681 corneal edema 9.8
682 spotted fever 9.8
683 chlamydia 9.8
684 allergic hypersensitivity disease 9.8
685 chagas disease 9.8
686 hepatitis a 9.8
687 quadriplegia 9.8
688 focal segmental glomerulosclerosis 9.8
689 polyneuropathy 9.8
690 labyrinthitis 9.8
691 echinococcosis 9.8
692 pericarditis 9.8
693 hyperuricemia 9.8
694 hypogonadism 9.8
695 hepatitis b 9.8
696 kidney cancer 9.8
697 iga glomerulonephritis 9.8
698 churg-strauss syndrome 9.8
699 central nervous system disease 9.8
700 gastritis 9.8
701 rhinitis 9.8
702 uremia 9.8
703 rapidly progressive glomerulonephritis 9.8
704 anti-basement membrane glomerulonephritis 9.8
705 poliomyelitis 9.8
706 pancreatitis 9.8
707 chronic inflammatory demyelinating polyradiculoneuropathy 9.8
708 demyelinating polyneuropathy 9.8
709 pituitary gland disease 9.8
710 hemolytic anemia 9.8
711 lymphopenia 9.8
712 influenza 9.8
713 nervous system disease 9.8
714 vasculitis 9.8
715 neuropathy 9.8
716 crohn's disease 9.8
717 hypersensitivity vasculitis 9.8
718 allergic angiitis 9.8
719 lymphocytic hypophysitis 9.8
720 microscopic polyangiitis 9.8
721 back pain 9.8
722 peripheral hypothyroidism 9.8
723 polyploidy 9.8
724 primary hypophysitis 9.8
725 thrombotic microangiopathy 9.8
726 spotted fever rickettsiosis 9.8
727 polyendocrinopathy 9.8
728 leukocyte disease 9.8 VEGFA CD8A CD40LG
729 autoimmune disease of central nervous system 9.8 IFNB1 CD8A CD40LG
730 breast angiosarcoma 9.8 VEGFA KDR
731 radiation proctitis 9.8 VEGFA KDR
732 aortic aneurysm, familial abdominal, 1 9.8
733 papillomatosis, confluent and reticulated 9.8
734 schistosoma mansoni infection, susceptibility/ 9.8
735 neural tube defects 9.8
736 lung cancer 9.8
737 celiac disease 1 9.8
738 hypervitaminosis a 9.8
739 immune deficiency disease 9.8
740 periodontitis, chronic 9.8
741 interstitial pneumonitis, desquamative, familial 9.8
742 dysphasia, familial developmental 9.8
743 stroke, ischemic 9.8
744 autoimmune lymphoproliferative syndrome 9.8
745 major depressive disorder 9.8
746 hepatitis c virus 9.8
747 aspergillosis 9.8
748 pulmonary hypertension, primary, 3 9.8
749 alacrima, achalasia, and mental retardation syndrome 9.8
750 marginal zone b-cell lymphoma 9.8
751 ameloblastoma 9.8
752 pain agnosia 9.8
753 specific language impairment 9.8
754 thrombosis 9.8
755 mucositis 9.8
756 osteonecrosis 9.8
757 cholelithiasis 9.8
758 q fever 9.8
759 visual epilepsy 9.8
760 denture stomatitis 9.8
761 goiter 9.8
762 otosclerosis 9.8
763 lagophthalmos 9.8
764 dental fluorosis 9.8
765 bacteriuria 9.8
766 cholera 9.8
767 candidiasis 9.8
768 urticaria 9.8
769 mental depression 9.8
770 giant cell reparative granuloma 9.8
771 amelogenesis imperfecta 9.8
772 keratopathy 9.8
773 lateral sclerosis 9.8
774 chondroma 9.8
775 irritant dermatitis 9.8
776 endometriosis 9.8
777 pulmonary tuberculosis 9.8
778 food allergy 9.8
779 mammary paget's disease 9.8
780 hyperglycemia 9.8
781 human immunodeficiency virus infectious disease 9.8
782 epithelial-myoepithelial carcinoma 9.8
783 acquired immunodeficiency syndrome 9.8
784 cerebrovascular disease 9.8
785 peptic ulcer disease 9.8
786 gastrointestinal system disease 9.8
787 actinomycosis 9.8
788 herpes zoster 9.8
789 decubitus ulcer 9.8
790 amyloidosis 9.8
791 achalasia 9.8
792 pathologic nystagmus 9.8
793 acanthamoeba keratitis 9.8
794 encephalocele 9.8
795 heavy metal poisoning 9.8
796 pyogenic granuloma 9.8
797 seizure disorder 9.8
798 spinal cord injury 9.8
799 integumentary system disease 9.8 VEGFA IL1A CD8A CD40LG
800 bone marrow cancer 9.8 VEGFA CD8A CD40LG
801 apnea, obstructive sleep 9.8
802 cardiac arrhythmia 9.8
803 fragile site, distamycin a type, rare, fra(16)(q22.1) 9.8
804 hernia, hiatus 9.8
805 meckel diverticulum 9.8
806 neutrophil migration 9.8
807 palmoplantar keratoderma, punctate type ii 9.8
808 ceroid lipofuscinosis, neuronal, 3 9.8
809 ceroid storage disease 9.8
810 enterocolitis 9.8
811 hemangiopericytoma, malignant 9.8
812 proteasome-associated autoinflammatory syndrome 1 9.8
813 niemann-pick disease, type c1 9.8
814 scott syndrome 9.8
815 hemophagocytic lymphohistiocytosis, familial, 1 9.8
816 nasopharyngeal carcinoma 9.8
817 parathyroid carcinoma 9.8
818 pseudofolliculitis barbae 9.8
819 pseudopseudohypoparathyroidism 9.8
820 carbonic anhydrase va deficiency, hyperammonemia due to 9.8
821 bacterial sepsis 9.8
822 autoimmune gastritis 9.8
823 hemophagocytic lymphohistiocytosis 9.8
824 foodborne botulism 9.8
825 adult t-cell leukemia 9.8
826 ocular albinism 9.8
827 sexual disorder 9.8
828 colitis 9.8
829 penicillin allergy 9.8
830 hypogonadotropic hypogonadism 9.8
831 sleeping sickness 9.8
832 trypanosomiasis 9.8
833 protein-losing enteropathy 9.8
834 polycystic ovary syndrome 9.8
835 choledocholithiasis 9.8
836 hemosiderosis 9.8
837 pancytopenia 9.8
838 hepatic coma 9.8
839 hypertrophic pyloric stenosis 9.8
840 hereditary hemorrhagic telangiectasia 9.8
841 telangiectasis 9.8
842 premature ejaculation 9.8
843 peptic esophagitis 9.8
844 adult-onset still's disease 9.8
845 niemann-pick disease 9.8
846 prostatitis 9.8
847 rheumatic fever 9.8
848 autoimmune hepatitis 9.8
849 hepatitis 9.8
850 acromegaly 9.8
851 hairy cell leukemia 9.8
852 cervix carcinoma 9.8
853 oligodendroglioma 9.8
854 chronic granulomatous disease 9.8
855 signet ring cell adenocarcinoma 9.8
856 hidradenoma 9.8
857 duodenum disease 9.8
858 clear cell renal cell carcinoma 9.8
859 t-cell lymphoblastic leukemia/lymphoma 9.8
860 stomach disease 9.8
861 gastric signet ring cell adenocarcinoma 9.8
862 duodenitis 9.8
863 perinatal necrotizing enterocolitis 9.8
864 bacterial pneumonia 9.8
865 mitochondrial encephalomyopathy 9.8
866 allergic asthma 9.8
867 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 9.8
868 hemorrhagic shock and encephalopathy syndrome 9.8
869 leukemia, t-cell, chronic 9.8
870 punctate porokeratosis 9.8
871 pure autonomic failure 9.8
872 ring chromosome 2 9.8
873 pulmonary arterial hypertension associated with portal hypertension 9.8
874 rare hereditary hemochromatosis 9.8
875 syndromic oculocutaneous albinism 9.8
876 acquired prothrombin deficiency 9.8
877 serotonin syndrome 9.8
878 fungal keratitis 9.8
879 hypopigmentation of the skin 9.8
880 retinal artery occlusion 9.7 VEGFA KDR F2
881 retinal vascular occlusion 9.7 VEGFA KDR F2
882 epithelioid hemangioendothelioma 9.7 VEGFA KDR
883 angiokeratoma circumscriptum 9.7 VEGFA KDR
884 alzheimer disease 9.7
885 amyotrophic lateral sclerosis 1 9.7
886 spondyloarthropathy 1 9.7
887 atrial standstill 1 9.7
888 alopecia, androgenetic, 1 9.7
889 gastroesophageal reflux 9.7
890 cervical rib 9.7
891 epidermoid cysts 9.7
892 diaphragmatic hernia, congenital 9.7
893 hypercholesterolemia, familial, 1 9.7
894 treacher collins syndrome 1 9.7
895 hemifacial microsomia 9.7
896 prader-willi syndrome 9.7
897 anencephaly 9.7
898 chondrosarcoma 9.7
899 cystic fibrosis 9.7
900 diabetes mellitus, type i 9.7
901 leprosy 3 9.7
902 myeloma, multiple 9.7
903 ocular motor apraxia 9.7
904 pancreatic agenesis 1 9.7
905 abnormal hair, joint laxity, and developmental delay 9.7
906 retinitis pigmentosa 9.7
907 graves disease 1 9.7
908 sarcoma, synovial 9.7
909 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.7
910 retinitis pigmentosa-deafness syndrome 9.7
911 oncocytoma 9.7
912 prostatic hyperplasia, benign 9.7
913 gallbladder disease 1 9.7
914 wilms tumor 5 9.7
915 brittle bone disorder 9.7
916 microvascular complications of diabetes 1 9.7
917 febrile seizures, familial, 4 9.7
918 langerhans cell histiocytosis 9.7
919 alveolar soft part sarcoma 9.7
920 anorexia nervosa 9.7
921 microvascular complications of diabetes 2 9.7
922 trichotillomania 9.7
923 beta-thalassemia 9.7
924 barrett esophagus 9.7
925 aortic valve disease 2 9.7
926 cholangiocarcinoma 9.7
927 global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies 9.7
928 megabladder, congenital 9.7
929 speech and communication disorders 9.7
930 angina pectoris 9.7
931 deficiency anemia 9.7
932 tendinitis 9.7
933 fusariosis 9.7
934 usher syndrome 9.7
935 posterior polar cataract 9.7
936 anaplastic large cell lymphoma 9.7
937 androgenic alopecia 9.7
938 scoliosis 9.7
939 inguinal hernia 9.7
940 lymphoproliferative syndrome 9.7
941 bone disease 9.7
942 fibrous dysplasia 9.7
943 thalassemia 9.7
944 endocarditis 9.7
945 siderosis 9.7
946 suppression amblyopia 9.7
947 rickets 9.7
948 hemiplegia 9.7
949 leech infestation 9.7
950 pulpitis 9.7
951 prostatic hypertrophy 9.7
952 primary hyperparathyroidism 9.7
953 diphtheria 9.7
954 constrictive pericarditis 9.7
955 melanoacanthoma 9.7
956 portal vein thrombosis 9.7
957 esophagitis 9.7
958 inflammatory spondylopathy 9.7
959 leiomyoma 9.7
960 uveitis 9.7
961 acute cystitis 9.7
962 background diabetic retinopathy 9.7
963 ehlers-danlos syndrome 9.7
964 tuberous sclerosis 9.7
965 eclampsia 9.7
966 biliary atresia 9.7
967 facial paralysis 9.7
968 amenorrhea 9.7
969 alcoholic liver cirrhosis 9.7
970 iritis 9.7
971 lymphangioma 9.7
972 ectropion 9.7
973 ventricular septal defect 9.7
974 heart septal defect 9.7
975 calcinosis 9.7
976 benign giant cell tumor 9.7
977 neuroma 9.7
978 enthesopathy 9.7
979 ankylosis 9.7
980 arteriosclerosis 9.7
981 pancreas disease 9.7
982 cystadenoma 9.7
983 prostatic adenoma 9.7
984 acinar cell carcinoma 9.7
985 allergic contact dermatitis 9.7
986 astrocytoma 9.7
987 cystic lymphangioma 9.7
988 gingival overgrowth 9.7
989 mood disorder 9.7
990 histiocytosis 9.7
991 pancreatic ductal adenocarcinoma 9.7
992 pseudohermaphroditism 9.7
993 extraskeletal chondroma 9.7
994 craniopharyngioma 9.7
995 primary syphilis 9.7
996 smooth muscle tumor 9.7
997 neuromuscular disease 9.7
998 fibrous histiocytoma 9.7
999 endophthalmitis 9.7
1000 intrahepatic cholangiocarcinoma 9.7
1001 myoblastoma 9.7
1002 paraplegia 9.7
1003 spondylitis 9.7
1004 juvenile rheumatoid arthritis 9.7
1005 macular holes 9.7
1006 peritonitis 9.7
1007 bullous pemphigoid 9.7
1008 oral cavity cancer 9.7
1009 myeloid sarcoma 9.7
1010 rubella 9.7
1011 intermediate coronary syndrome 9.7
1012 lethal midline granuloma 9.7
1013 pemphigus 9.7
1014 keratoconjunctivitis 9.7
1015 iridocyclitis 9.7
1016 blepharitis 9.7
1017 fatty liver disease 9.7
1018 bronchiectasis 9.7
1019 fasciitis 9.7
1020 plantar fasciitis 9.7
1021 substance dependence 9.7
1022 myotonic dystrophy 9.7
1023 dentinogenesis imperfecta type 2 9.7
1024 hansen's disease 9.7
1025 hemangioendothelioma 9.7
1026 labrador lung 9.7
1027 lymphosarcoma 9.7
1028 osteochondroma 9.7
1029 plasmablastic lymphoma 9.7
1030 superior limbic keratoconjunctivitis 9.7
1031 rare lymphatic malformation 9.7
1032 avascular necrosis 9.7
1033 premature aging 9.7
1034 rare tumor 9.7
1035 cavernous hemangioma 9.7 VEGFA KDR F2
1036 angioimmunoblastic t-cell lymphoma 9.7 VEGFA SYK KDR
1037 blood coagulation disease 9.7 VEGFA F3 F2 CD8A CD40LG
1038 blood platelet disease 9.7 VEGFA F3 F2 CD8A CD40LG
1039 varicose veins 9.7 VEGFA KDR F2
1040 primary cutaneous b-cell lymphoma 9.7 VEGFA KDR
1041 viral encephalitis 9.6 VEGFA IFNB1 CD8A CD40LG
1042 capillary disease 9.6 VEGFA KDR CD8A
1043 placental insufficiency 9.6 VEGFA KDR F3 F2
1044 acanthosis nigricans 9.5
1045 apert syndrome 9.5
1046 pfeiffer syndrome 9.5
1047 cerebral amyloid angiopathy, cst3-related 9.5
1048 aniridia 1 9.5
1049 ankyloglossia with or without tooth anomalies 9.5
1050 basal cell nevus syndrome 9.5
1051 bladder cancer 9.5
1052 progressive familial heart block, type ia 9.5
1053 cleft soft palate 9.5
1054 clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly 9.5
1055 crouzon syndrome 9.5
1056 deafness, unilateral 9.5
1057 dens evaginatus 9.5
1058 dermal ridges-off-the-end 9.5
1059 multiple sclerosis 9.5
1060 distichiasis 9.5
1061 fibrodysplasia ossificans progressiva 9.5
1062 corneal dystrophy, fuchs endothelial, 1 9.5
1063 hand skill, relative 9.5
1064 hemifacial atrophy, progressive 9.5
1065 huntington disease 9.5
1066 renal cell carcinoma, nonpapillary 9.5
1067 hypertriglyceridemia, familial 9.5
1068 laryngomalacia 9.5
1069 acrofacial dysostosis 1, nager type 9.5
1070 maxillonasal dysplasia, binder type 9.5
1071 myoclonus and ataxia 9.5
1072 multiple endocrine neoplasia, type iib 9.5
1073 ocular cicatricial pemphigoid 9.5
1074 optic nerve hypoplasia, bilateral 9.5
1075 pachyonychia congenita 1 9.5
1076 pheochromocytoma 9.5
1077 pneumothorax, primary spontaneous 9.5
1078 kindler syndrome 9.5
1079 variegate porphyria 9.5
1080 exfoliation syndrome 9.5
1081 pulmonary fibrosis, idiopathic 9.5
1082 pulmonary hypertension, primary, 1 9.5
1083 scheuermann disease 9.5
1084 small cell cancer of the lung 9.5
1085 spondylolisthesis 9.5
1086 sturge-weber syndrome 9.5
1087 teeth, supernumerary 9.5
1088 testicular torsion 9.5
1089 digeorge syndrome 9.5
1090 thyroid cancer, nonmedullary, 1 9.5
1091 tobacco addiction 9.5
1092 trichodentoosseous syndrome 9.5
1093 suppressor of tumorigenicity 3 9.5
1094 vesicoureteral reflux 1 9.5
1095 volvulus of midgut 9.5
1096 alstrom syndrome 9.5
1097 anemia, autoimmune hemolytic 9.5
1098 ascites, chylous 9.5
1099 corpus callosum, agenesis of 9.5
1100 fanconi anemia, complementation group a 9.5
1101 galactorrhea 9.5
1102 galactosemia i 9.5
1103 hemochromatosis, type 1 9.5
1104 netherton syndrome 9.5
1105 3-methylglutaconic aciduria, type iii 9.5
1106 peters-plus syndrome 9.5
1107 pili torti, early-onset 9.5
1108 pycnodysostosis 9.5
1109 knobloch syndrome 1 9.5
1110 sudden infant death syndrome 9.5
1111 werner syndrome 9.5
1112 wernicke-korsakoff syndrome 9.5
1113 muscular dystrophy, duchenne type 9.5
1114 budd-chiari syndrome 9.5
1115 supranuclear palsy, progressive, 1 9.5
1116 chudley-mccullough syndrome 9.5
1117 panbronchiolitis, diffuse 9.5
1118 temtamy preaxial brachydactyly syndrome 9.5
1119 abdominal obesity-metabolic syndrome 1 9.5
1120 late-onset retinal degeneration 9.5
1121 aneurysmal bone cysts 9.5
1122 gastrointestinal stromal tumor 9.5
1123 allergic rhinitis 9.5
1124 epileptic encephalopathy, early infantile, 6 9.5
1125 resting heart rate, variation in 9.5
1126 patent ductus arteriosus 1 9.5
1127 bulimia nervosa 9.5
1128 endometrial cancer 9.5
1129 kala-azar 1 9.5
1130 granulomatosis with polyangiitis 9.5
1131 respiratory rhythmicity in sleep 9.5
1132 esophagitis, eosinophilic, 1 9.5
1133 retinitis pigmentosa 33 9.5
1134 asthma-related traits 4 9.5
1135 cavitary optic disc anomalies 9.5
1136 cataract 47 9.5
1137 smoking as a quantitative trait locus 3 9.5
1138 histiocytoma, angiomatoid fibrous 9.5
1139 ewing sarcoma 9.5
1140 acute promyelocytic leukemia 9.5
1141 lung cancer susceptibility 3 9.5
1142 multiple sclerosis 2 9.5
1143 retinitis pigmentosa 27 9.5
1144 graft-versus-host disease 9.5
1145 cerebellar ataxia, neuropathy, and vestibular areflexia syndrome 9.5
1146 leukemia, acute lymphoblastic 3 9.5
1147 megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2 9.5
1148 lung disease, immunodeficiency, and chromosome breakage syndrome 9.5
1149 mulchandani-bhoj-conlin syndrome 9.5
1150 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.5
1151 tendinopathy 9.5
1152 angiosarcoma 9.5
1153 invasive aspergillosis 9.5
1154 acute diarrhea 9.5
1155 trichomonas vaginalis trichomoniasis 9.5
1156 aniseikonia 9.5
1157 hypophosphatemia 9.5
1158 variola major 9.5
1159 lennox-gastaut syndrome 9.5
1160 orofacial cleft 9.5
1161 intestinal schistosomiasis 9.5
1162 small cell carcinoma 9.5
1163 fetal alcohol spectrum disorder 9.5
1164 chorioamnionitis 9.5
1165 autosomal recessive disease 9.5
1166 paraganglioma 9.5
1167 primary progressive multiple sclerosis 9.5
1168 rheumatic heart disease 9.5
1169 fragile x-associated tremor/ataxia syndrome 9.5
1170 adrenal gland pheochromocytoma 9.5
1171 mucosal melanoma 9.5
1172 infective endocarditis 9.5
1173 munchausen by proxy 9.5
1174 cutaneous t cell lymphoma 9.5
1175 osteoblastoma 9.5
1176 brain meningioma 9.5
1177 heavy chain disease 9.5
1178 anosognosia 9.5
1179 crohn's colitis 9.5
1180 idiopathic scoliosis 9.5
1181 congenital ptosis 9.5
1182 metal allergy 9.5
1183 salmonellosis 9.5
1184 isolated growth hormone deficiency 9.5
1185 autosomal dominant non-syndromic intellectual disability 2 9.5
1186 physical disorder 9.5
1187 cakut 9.5
1188 non-alcoholic fatty liver disease 9.5
1189 nodal marginal zone lymphoma 9.5
1190 igg4-related disease 9.5
1191 desmoid tumor 9.5
1192 non-alcoholic steatohepatitis 9.5
1193 benign teratoma 9.5
1194 middle east respiratory syndrome 9.5
1195 aortic dissection 9.5
1196 usher syndrome type 2 9.5
1197 dry eye syndrome 9.5
1198 ehrlichiosis 9.5
1199 mumps 9.5
1200 left bundle branch hemiblock 9.5
1201 sialadenitis 9.5
1202 klippel-feil syndrome 9.5
1203 hypopyon 9.5
1204 glucose intolerance 9.5
1205 lactose intolerance 9.5
1206 microphthalmia 9.5
1207 filariasis 9.5
1208 gastric ulcer 9.5
1209 salivary gland disease 9.5
1210 abducens nerve disease 9.5
1211 kuhnt-junius degeneration 9.5
1212 borderline personality disorder 9.5
1213 intracranial aneurysm 9.5
1214 bullous keratopathy 9.5
1215 hydronephrosis 9.5
1216 cholecystolithiasis 9.5
1217 anogenital venereal wart 9.5
1218 opioid abuse 9.5
1219 trachoma 9.5
1220 arteriovenous malformation 9.5
1221 erysipelas 9.5
1222 mitral valve insufficiency 9.5
1223 autonomic neuropathy 9.5
1224 fissured tongue 9.5
1225 hypertensive heart disease 9.5
1226 fuchs' endothelial dystrophy 9.5
1227 infant gynecomastia 9.5
1228 presbyopia 9.5
1229 cicatricial pemphigoid 9.5
1230 gestational diabetes 9.5
1231 emery-dreifuss muscular dystrophy 9.5
1232 clubfoot 9.5
1233 hypertrophic cardiomyopathy 9.5
1234 optic neuritis 9.5
1235 alveolar echinococcosis 9.5
1236 filarial elephantiasis 9.5
1237 shigellosis 9.5
1238 tinea pedis 9.5
1239 secondary hyperparathyroidism 9.5
1240 retinal perforation 9.5
1241 paracoccidioidomycosis 9.5
1242 acoustic neuroma 9.5
1243 gynecomastia 9.5
1244 cardiovascular system disease 9.5
1245 sialolithiasis 9.5
1246 conduct disorder 9.5
1247 carotid stenosis 9.5
1248 dementia 9.5
1249 crescentic glomerulonephritis 9.5
1250 brain cancer 9.5
1251 cholestasis 9.5
1252 familial hypercholesterolemia 9.5
1253 sick sinus syndrome 9.5
1254 irregular astigmatism 9.5
1255 hypophosphatasia 9.5
1256 oral candidiasis 9.5
1257 sclerosing cholangitis 9.5
1258 shoulder impingement syndrome 9.5
1259 corneal ectasia 9.5
1260 personality disorder 9.5
1261 panniculitis 9.5
1262 angioedema 9.5
1263 endogenous depression 9.5
1264 intraductal papilloma 9.5
1265 melanotic neuroectodermal tumor 9.5
1266 neovascular glaucoma 9.5
1267 duodenal ulcer 9.5
1268 histoplasmosis 9.5
1269 mitral valve stenosis 9.5
1270 facial hemiatrophy 9.5
1271 factitious disorder 9.5
1272 ossifying fibroma 9.5
1273 neuritis 9.5
1274 epilepsy 9.5
1275 bone cancer 9.5
1276 atrial heart septal defect 9.5
1277 malignant fibrous histiocytoma 9.5
1278 dysostosis 9.5
1279 trichomoniasis 9.5
1280 leiomyosarcoma 9.5
1281 cerebral palsy 9.5
1282 tularemia 9.5
1283 myeloproliferative neoplasm 9.5
1284 pharyngitis 9.5
1285 spondylolysis 9.5
1286 craniosynostosis 9.5
1287 iron metabolism disease 9.5
1288 granular cell tumor 9.5
1289 gangliocytoma 9.5
1290 glomus tumor 9.5
1291 psychotic disorder 9.5
1292 chronic conjunctivitis 9.5
1293 testicular disease 9.5
1294 chondromalacia 9.5
1295 opiate dependence 9.5
1296 retinal drusen 9.5
1297 cystic teratoma 9.5
1298 transitional cell carcinoma 9.5
1299 ossifying fibromyxoid tumor 9.5
1300 phimosis 9.5
1301 capillary hemangioma 9.5
1302 auditory system disease 9.5
1303 tic disorder 9.5
1304 bruxism 9.5
1305 cryoglobulinemia 9.5
1306 periarthritis 9.5
1307 pleomorphic adenoma carcinoma 9.5
1308 testicular cancer 9.5
1309 thoracic outlet syndrome 9.5
1310 papillary cystadenocarcinoma 9.5
1311 cystadenocarcinoma 9.5
1312 papillary adenocarcinoma 9.5
1313 multiple endocrine neoplasia 9.5
1314 proctitis 9.5
1315 lipomatosis 9.5
1316 hand dermatosis 9.5
1317 inverted papilloma 9.5
1318 lysosomal storage disease 9.5
1319 temporal lobe epilepsy 9.5
1320 mesenchymal cell neoplasm 9.5
1321 bacterial vaginosis 9.5
1322 laryngitis 9.5
1323 necrobiosis lipoidica 9.5
1324 cellulitis 9.5
1325 sertoli cell tumor 9.5
1326 angiolipoma 9.5
1327 central nervous system cancer 9.5
1328 ovary adenocarcinoma 9.5
1329 extramedullary plasmacytoma 9.5
1330 plasmacytoma 9.5
1331 theileriasis 9.5
1332 verrucous carcinoma 9.5
1333 pituitary adenoma 9.5
1334 multidrug-resistant tuberculosis 9.5
1335 spindle cell carcinoma 9.5
1336 duodenogastric reflux 9.5
1337 tricuspid valve insufficiency 9.5
1338 agnosia 9.5
1339 mutism 9.5
1340 angiomyoma 9.5
1341 pigmented basal cell carcinoma 9.5
1342 bone giant cell tumor 9.5
1343 radiculopathy 9.5
1344 myofascial pain syndrome 9.5
1345 erdheim-chester disease 9.5
1346 burning mouth syndrome 9.5
1347 amelanotic melanoma 9.5
1348 occupational dermatitis 9.5
1349 dyslexia 9.5
1350 clear cell adenocarcinoma 9.5
1351 avian influenza 9.5
1352 bile duct cancer 9.5
1353 prostate disease 9.5
1354 calciphylaxis 9.5
1355 ganglioneuroma 9.5
1356 adenosquamous carcinoma 9.5
1357 postpoliomyelitis syndrome 9.5
1358 essential tremor 9.5
1359 thyroid gland disease 9.5
1360 urinary tract obstruction 9.5
1361 infertility 9.5
1362 epulis 9.5
1363 colonic disease 9.5
1364 paget's disease of bone 9.5
1365 dystonia 9.5
1366 monophasic synovial sarcoma 9.5
1367 mature teratoma 9.5
1368 t-cell acute lymphoblastic leukemia 9.5
1369 diffuse pulmonary fibrosis 9.5
1370 verruciform xanthoma of skin 9.5
1371 pediatric lymphoma 9.5
1372 panic disorder 9.5
1373 congestive heart failure 9.5
1374 epithelioid sarcoma 9.5
1375 thyroid hyalinizing trabecular adenoma 9.5
1376 inflammatory breast carcinoma 9.5
1377 prion disease 9.5
1378 connective tissue disease 9.5
1379 spinal stenosis 9.5
1380 thyroiditis 9.5
1381 congenital epulis 9.5
1382 parathyroid adenoma 9.5
1383 muscular atrophy 9.5
1384 hyperthyroidism 9.5
1385 polycythemia 9.5
1386 polyhydramnios 9.5
1387 herpes simplex 9.5
1388 ulcerative colitis 9.5
1389 smallpox 9.5
1390 atrophic gastritis 9.5
1391 cervix uteri carcinoma in situ 9.5
1392 leishmaniasis 9.5
1393 mucocutaneous leishmaniasis 9.5
1394 speech disorder 9.5
1395 lichen planus 9.5
1396 ocular hypertension 9.5
1397 scotoma 9.5
1398 exophthalmos 9.5
1399 intracranial hypertension 9.5
1400 exposure keratitis 9.5
1401 meningitis 9.5
1402 postpartum depression 9.5
1403 dacryoadenitis 9.5
1404 neurofibroma 9.5
1405 congenital nystagmus 9.5
1406 placental abruption 9.5
1407 noma 9.5
1408 vitreous detachment 9.5
1409 irritable bowel syndrome 9.5
1410 polyarteritis nodosa 9.5
1411 alopecia areata 9.5
1412 developmental coordination disorder 9.5
1413 hypoplastic left heart syndrome 9.5
1414 drug dependence 9.5
1415 hypoglycemia 9.5
1416 bap1 tumor predisposition syndrome 9.5
1417 amyloid neuropathy 9.5
1418 aneurysm of sinus of valsalva 9.5
1419 auditory neuropathy spectrum disorder 9.5
1420 brain tumor, childhood 9.5
1421 candida glabrata 9.5
1422 cervical intraepithelial neoplasia 9.5
1423 chromosomal triplication 9.5
1424 cleft tongue 9.5
1425 complete androgen insensitivity syndrome 9.5
1426 congenital cytomegalovirus 9.5
1427 corticobasal degeneration 9.5
1428 craniofacial microsomia 9.5
1429 dwarfism 9.5
1430 erythrokeratoderma ''en cocardes'' 9.5
1431 familial tumoral calcinosis 9.5
1432 glossodynia 9.5
1433 growth hormone deficiency 9.5
1434 haemophilus influenzae 9.5
1435 inflammatory linear verrucous epidermal nevus 9.5
1436 lymphomatoid granulomatosis 9.5
1437 mercury poisoning 9.5
1438 nephrogenic systemic fibrosis 9.5
1439 oral lichen planus 9.5
1440 pili torti 9.5
1441 single ventricular heart 9.5
1442 stenotrophomonas maltophilia infection 9.5
1443 stevens-johnson syndrome/toxic epidermal necrolysis 9.5
1444 superficial spreading melanoma 9.5
1445 tetraploidy 9.5
1446 tièche-jadassohn nevus 9.5
1447 uterine sarcoma 9.5
1448 weber syndrome 9.5
1449 raynaud phenomenon 9.5
1450 clopidogrel resistance 9.5
1451 cryptogenic cirrhosis 9.5
1452 brain injury 9.5
1453 cerebral aneurysms 9.5
1454 developmental dyspraxia 9.5
1455 encephalopathy 9.5
1456 foot drop 9.5
1457 neuronal migration disorders 9.5
1458 tremor 9.5
1459 b-cell non-hodgkin lymphoma 9.5
1460 t-cell non-hodgkin lymphoma 9.5
1461 submucosal cleft palate 9.5
1462 nasopharyngeal teratoma 9.5
1463 epignathus 9.5
1464 nevus of ota 9.5
1465 congenital temporomandibular joint ankylosis 9.5
1466 rare vascular tumor 9.5
1467 virus-associated trichodysplasia spinulosa 9.5
1468 epstein-barr virus-associated gastric carcinoma 9.5
1469 combined pulmonary fibrosis-emphysema syndrome 9.5
1470 indolent b-cell non-hodgkin lymphoma 9.5
1471 myospherulosis 9.5
1472 keratocystic odontogenic tumor 9.5
1473 paraquat poisoning 9.5
1474 rare soft tissue tumor 9.5
1475 benign idiopathic neonatal seizures 9.5
1476 discoid lupus erythematosus 9.5
1477 transient pseudohypoaldosteronism 9.5
1478 microtia 9.5
1479 thyroid carcinoma 9.5
1480 alpha-heavy chain disease 9.5
1481 hypoplastic amelogenesis imperfecta 9.5
1482 precursor t-cell acute lymphoblastic leukemia 9.5
1483 herpangina 9.5 IRF3 IFNB1 CD8A CD40LG
1484 coronavirus infectious disease 9.5 IRF3 IFNB1 CD8A CD40LG
1485 intussusception 9.4 VEGFA KDR CDH5 CD40LG
1486 vein disease 9.4 VEGFA KDR F3 F2 CD40LG
1487 gliosarcoma 9.2 VEGFA KDR IFNB1 CD8A
1488 hematologic cancer 9.1 VEGFA SYK KDR CD8A CD40LG
1489 behcet syndrome 8.8 VEGFA LTA IL1A IFNB1 HOXA1 F2

Graphical network of the top 20 diseases related to Hantavirus Pulmonary Syndrome:



Diseases related to Hantavirus Pulmonary Syndrome

Symptoms & Phenotypes for Hantavirus Pulmonary Syndrome

MGI Mouse Phenotypes related to Hantavirus Pulmonary Syndrome:

45 (showing 11, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 CD40LG CD8A CDH5 F2 F3 HOXA1
2 homeostasis/metabolism MP:0005376 10.28 CD40LG CDH5 F2 F3 HOXA1 IFNB1
3 immune system MP:0005387 10.28 CD40LG CD8A CDH5 F2 F3 HOXA1
4 cardiovascular system MP:0005385 10.24 CD40LG CDH5 F2 F3 HOXA1 IL1A
5 cellular MP:0005384 10.22 CD40LG CD8A CDH5 F2 F3 HOXA1
6 integument MP:0010771 10.11 CD40LG CD8A CDH5 F2 F3 IL1A
7 nervous system MP:0003631 10.1 CD40LG CD8A F2 F3 HOXA1 IFNB1
8 normal MP:0002873 9.91 CD8A CDH5 F2 F3 HOXA1 IFNB1
9 respiratory system MP:0005388 9.81 F2 F3 HOXA1 IRF3 KDR LTA
10 skeleton MP:0005390 9.61 CD40LG F2 HOXA1 IFNB1 KDR LTA
11 vision/eye MP:0005391 9.23 CDH5 F3 HOXA1 IRF3 KDR LTA

Drugs & Therapeutics for Hantavirus Pulmonary Syndrome

Drugs for Hantavirus Pulmonary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 25, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
2
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
3
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
4
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
5 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
6
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
7 Gastrointestinal Agents Phase 2
8 Methylprednisolone Acetate Phase 2
9 Hormones Phase 2
10 Antineoplastic Agents, Hormonal Phase 2
11 Antiemetics Phase 2
12 Neuroprotective Agents Phase 2
13 Hormone Antagonists Phase 2
14 glucocorticoids Phase 2
15 Protective Agents Phase 2
16 Anti-Inflammatory Agents Phase 2
17 polysaccharide-K Phase 1
18 Vaccines Phase 1
19 Immunologic Factors Phase 1
20 Antithrombins
21 Antithrombin III
22 Immunoglobulins
23 Antibodies
24 Anti-Bacterial Agents
25 Antibiotics, Antitubercular

Interventional clinical trials:

(showing 13, show less)
# Name Status NCT ID Phase Drugs
1 A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Methylprednisolone as a Treatment for Presumed Hantavirus Cardiopulmonary Syndrome Completed NCT00128180 Phase 2 Methylprednisolone;Placebo
2 Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial Recruiting NCT04375098 Phase 2
3 A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in the 121st Combat Support Hospital (Seoul, Korea) Enrolling by invitation NCT00623168 Phase 2 Ribavirin
4 A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in Landstuhl Regional Medical Center (Landstuhl, Germany) IND 16,666 Withdrawn NCT00868946 Phase 2 Virazole (Ribavirin)
5 A Phase I, Randomized, Placebo Controlled, Double-Blind, Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection System in Normal Healthy Adults Active, not recruiting NCT03682107 Phase 1
6 A Phase 1, Randomized Trial to Assess the Safety, Reactogenicity, and Immunogenicity of a Combination HTNV and PUUV DNA Vaccine Candidate Administered by Electroporation Enrolling by invitation NCT03718130 Phase 1
7 A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome Completed NCT00001123 Ribavirin
8 Prospective Follow Up of Household Contacts and Hantavirus Transmission Study Among Index and Additional Cases in Chile Completed NCT00533767
9 Hantavirus Registry - HantaReg Recruiting NCT04323904
10 Covid-19 Associated Nephritis as Early Predictor for Complicated Course of Disease Recruiting NCT04347824
11 Puumala Hantavirus Infection in France: Evaluation of Commercial Assays for the Detection of Antibodies Against This Virus and the Use of Urine Samples for the Molecular Detection of This Infection Recruiting NCT02455375
12 The Impact of the Coronavirus Disease 2019 (Covid-19) Outbreak on Emergency Room Attendances of Surgical Patients at a Tertiary Medical Center Recruiting NCT04338672
13 Real World Study of Classic Infectious Disease Recruiting NCT04020536 Antibiotics

Search NIH Clinical Center for Hantavirus Pulmonary Syndrome

Cochrane evidence based reviews: hantavirus pulmonary syndrome

Genetic Tests for Hantavirus Pulmonary Syndrome

Genetic tests related to Hantavirus Pulmonary Syndrome:

# Genetic test Affiliating Genes
1 Hantavirus Pulmonary Syndrome 29

Anatomical Context for Hantavirus Pulmonary Syndrome

MalaCards organs/tissues related to Hantavirus Pulmonary Syndrome:

40
Lung, Endothelial, Testes, T Cells, Kidney, Whole Blood, Monocytes

Publications for Hantavirus Pulmonary Syndrome

Articles related to Hantavirus Pulmonary Syndrome:

(showing 683, show less)
# Title Authors PMID Year
1
Atypical case of hantavirus infection in Sri Lanka mimicking leptospirosis: a case report. 61
32552909 2020
2
Development of small-molecule inhibitors against hantaviruses. 61
32445882 2020
3
New data about home range and movements of Oligoryzomys flavescens (Rodentia: Cricetidae) help to understand the spread and transmission of Andes virus that causes Hantavirus Pulmonary Syndrome. 61
32034891 2020
4
Person-to-Person Transmission of Andes Virus in Hantavirus Pulmonary Syndrome, Argentina, 2014. 61
32186494 2020
5
Home range variability, spatial aggregation, and excursions of Akodon azarae and Oligoryzomys flavescens in Pampean agroecosystems. 61
32304184 2020
6
Long-Term Rodent Surveillance after Outbreak of Hantavirus Infection, Yosemite National Park, California, USA, 2012. 61
32091360 2020
7
Hantavirus inhibits apoptosis by preventing mitochondrial membrane potential loss through up-regulation of the pro-survival factor BCL-2. 61
32032391 2020
8
Hantavirus Infection with Renal Failure and Proteinuria, Colorado, USA, 2019. 61
31961310 2020
9
Sociocultural determinants of adoption of preventive practices for hantavirus: A knowledge, attitudes, and practices survey in Tonosí, Panama. 61
32107494 2020
10
Hantavirus Pulmonary Syndrome in Traveler Returning from Nepal to Spain. 61
31674901 2020
11
Development of RT-qPCR and semi-nested RT-PCR assays for molecular diagnosis of hantavirus pulmonary syndrome. 61
31877142 2019
12
Mechanisms of Hantavirus Transmission in Oligoryzomys longicaudatus. 61
31792647 2019
13
Detection of New World Hantavirus Antibodies in Rodents of Eastern New Mexico, USA. 61
31021684 2019
14
New Exposure Location for Hantavirus Pulmonary Syndrome Case, California, USA, 2018. 61
31538924 2019
15
Hantavirus Pulmonary Syndrome Risk in Entre Ríos, Argentina. 61
31338625 2019
16
Notes from the Field: Hantavirus Pulmonary Syndrome - Denver, Colorado, 2018. 61
31487276 2019
17
Dendritic Cells (DCs) as "Fire Accelerants" of Hantaviral Pathogenesis. 61
31540199 2019
18
Epidemiological description, case-fatality rate, and trends of Hantavirus Pulmonary Syndrome: 9 years of surveillance in Argentina. 61
30840775 2019
19
Progress on the Prevention and Treatment of Hantavirus Disease. 61
31277410 2019
20
Current Situation and Perspectives on Hantaviruses in Mexico. 61
31336858 2019
21
Unique Interferon Pathway Regulation by the Andes Virus Nucleocapsid Protein Is Conferred by Phosphorylation of Serine 386. 61
30867297 2019
22
Malaria and Hantavirus Pulmonary Syndrome in Gold Mining in the Amazon Region, Brazil. 61
31130600 2019
23
[HANTAVIRUS PULMONARY SYNDROME DIAGNOSED IN A RETURNED TRAVELER FROM THE USA]. 61
31104390 2019
24
Innate and adaptive immune responses against human Puumala virus infection: immunopathogenesis and suggestions for novel treatment strategies for severe hantavirus-associated syndromes. 61
30663801 2019
25
Serum Markers Associated with Severity and Outcome of Hantavirus Pulmonary Syndrome. 61
30698699 2019
26
Capillary leak-syndrome triggered by Maripa virus in French Guiana: case report and implication for pathogenesis. 61
30876401 2019
27
The ecological dynamics of hantavirus diseases: From environmental variability to disease prevention largely based on data from China. 61
30789905 2019
28
Orthohantaviruses belonging to three phylogroups all inhibit apoptosis in infected target cells. 61
30696898 2019
29
Hantavirus entry: Perspectives and recent advances. 61
31439149 2019
30
Hantavirus pulmonary syndrome in children: case report and case series from an endemic area of Brazil. 61
31859842 2019
31
Two Point Mutations in Old World Hantavirus Glycoproteins Afford the Generation of Highly Infectious Recombinant Vesicular Stomatitis Virus Vectors. 61
30622188 2019
32
Immunocytochemical and Ultrastructural Evidence Supporting That Andes Hantavirus (ANDV) Is Transmitted Person-to-Person Through the Respiratory and/or Salivary Pathways. 61
31998273 2019
33
Expansion of the range of Necromys lasiurus (Lund, 1841) into open areas of the Atlantic Forest biome in Rio de Janeiro state, Brazil, and the role of the species as a host of the hantavirus. 61
30149024 2018
34
Protocadherin-1 is essential for cell entry by New World hantaviruses. 61
30464266 2018
35
Notes from the Field: Exported Case of Sin Nombre Hantavirus Pulmonary Syndrome - Israel, 2017. 61
30307906 2018
36
Maripa Virus RNA Load and Antibody Response in Hantavirus Pulmonary Syndrome, French Guiana. 61
30124408 2018
37
Complete Genome Sequences of Monongahela Hantavirus from Pennsylvania, USA. 61
30533642 2018
38
Innate immune responses elicited by Sin Nombre virus or type I IFN agonists protect hamsters from lethal Andes virus infections. 61
30067171 2018
39
Rats! Hantavirus: A Case Report of a Suspected Case in Eastern Tennessee. 61
30010530 2018
40
Distributional ecology of Andes hantavirus: a macroecological approach. 61
29929522 2018
41
Space Use and Social Mating System of the Hantavirus Host, Oligoryzomys longicaudatus. 61
29196828 2018
42
Habitat, species richness and hantaviruses of sigmodontine rodents within the Interior Atlantic Forest, Paraguay. 61
30067840 2018
43
[Outbreak of hantavirus pulmonary syndrome in Tucumán, Argentina]. 61
29940540 2018
44
Two Atypical Cases of Hantavirus Infections from Sri Lanka. 61
29850303 2018
45
A Nonfatal Case of Dobrava Hantavirus Hemorrhagic Fever with Renal Syndrome Combined with Hantavirus Cardiopulmonary Syndrome. 61
29563720 2018
46
The Impact of Global Environmental Changes on Infectious Disease Emergence with a Focus on Risks for Brazil. 61
29253158 2017
47
Targeted inhibition of hantavirus replication and intracranial pathogenesis by a chimeric protein-delivered siRNA. 61
29017779 2017
48
Epidemic hemorrhagic fever complicated with late pregnancy: A case report. 61
28984763 2017
49
A lethal disease model for New World hantaviruses using immunosuppressed Syrian hamsters. 61
29077702 2017
50
Hantavirus Pulmonary Syndrome Caused by Maripa Virus in French Guiana, 2008-2016. 61
28930019 2017
51
Clinical aspects of hantavirus infections in Bulgaria. 61
28229289 2017
52
Circulation and diagnostics of Puumala virus in Norway: nephropatia epidemica incidence and rodent population dynamics. 61
28585306 2017
53
High-resolution computed tomography findings in hantavirus pulmonary syndrome. 61
28894346 2017
54
Hantavirus and tuberculosis co-infection in an Indian child. 61
29063892 2017
55
A Fatal Hantavirus Pulmonary Syndrome Misdiagnosed as Dengue: An Investigation into the First Reported Case in Rio de Janeiro State, Brazil. 61
28719302 2017
56
Exposure Characteristics of Hantavirus Pulmonary Syndrome Patients, United States, 1993-2015. 61
28418312 2017
57
Massive plasmablast response elicited in the acute phase of hantavirus pulmonary syndrome. 61
28106253 2017
58
High-resolution computed tomography findings in eight patients with hantavirus pulmonary syndrome. 61
28670025 2017
59
A rare cause of acute pancreatitis: Hantavirus infection. 61
29364099 2017
60
Role of the Medical Examiner in Zika Virus and Other Emerging Infections. 61
27608262 2017
61
Serum Cytokine Profiles Differentiating Hemorrhagic Fever with Renal Syndrome and Hantavirus Pulmonary Syndrome. 61
28572804 2017
62
Infection resistance and tolerance in Peromyscus spp., natural reservoirs of microbes that are virulent for humans. 61
27381345 2017
63
Hantavirus pulmonary syndrome in Tucumán province associated to an unexpected viral genotype. 61
28463210 2017
64
Notes from the Field: Hantavirus Pulmonary Syndrome in a Migrant Farm Worker - Colorado, 2016. 61
28103211 2017
65
Hantavirus Pulmonary Syndrome: High-resolution Computed Tomography Findings. 61
27460995 2017
66
Evaluation of habitat requirements of small rodents and effectiveness of an ecologically-based management in a hantavirus-endemic natural protected area in Argentina. 61
27135773 2017
67
Community-Acquired Pneumonia in Latin America. 61
27960210 2016
68
The Andes Virus Nucleocapsid Protein Directs Basal Endothelial Cell Permeability by Activating RhoA. 61
27795403 2016
69
Mechanistic Insight into Bunyavirus-Induced Membrane Fusion from Structure-Function Analyses of the Hantavirus Envelope Glycoprotein Gc. 61
27783711 2016
70
Hantavirus pulmonary syndrome in a postpartum woman. 61
27688634 2016
71
Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome. 61
27233645 2016
72
Inhibition of the Hantavirus Fusion Process by Predicted Domain III and Stem Peptides from Glycoprotein Gc. 61
27414047 2016
73
Depletion of Alveolar Macrophages Does Not Prevent Hantavirus Disease Pathogenesis in Golden Syrian Hamsters. 61
27099308 2016
74
Environmental Variables Associated with Hantavirus Reservoirs and Other Small Rodent Species in Two National Parks in the Paraná Delta, Argentina: Implications for Disease Prevention. 61
27169561 2016
75
Molecular Diagnosis of Hemorrhagic Fever with Renal Syndrome Caused by Puumala Virus. 61
26962084 2016
76
Phylogeographic analysis of hemorrhagic fever with renal syndrome patients using multiplex PCR-based next generation sequencing. 61
27221218 2016
77
Genetic characterization of hantaviruses isolated from rodents in the port cities of Heilongjiang, China, in 2014. 61
27038799 2016
78
Hantavirus pulmonary syndrome in a highly endemic area of Brazil. 61
26464248 2016
79
Hantavirus pulmonary syndrome and rodent reservoirs in the savanna-like biome of Brazil's southeastern region. 61
26541807 2016
80
Ten years of a hantavirus disease emergency in the Federal District, Brazil. 61
27163562 2016
81
Fugong virus, a novel hantavirus harbored by the small oriental vole (Eothenomys eleusis) in China. 61
26880191 2016
82
Bonded-communities in HantaVirus research: a research collaboration network (RCN) analysis. 61
32287514 2016
83
Hantavirus Infection Suppresses Thrombospondin-1 Expression in Cultured Endothelial Cells in a Strain-Specific Manner. 61
27486439 2016
84
Laguna Negra Virus Infection Causes Hantavirus Pulmonary Syndrome in Turkish Hamsters (Mesocricetus brandti). 61
25722219 2016
85
A Cluster of Three Cases of Hantavirus Pulmonary Syndrome among Canadian Military Personnel. 61
27366160 2016
86
Comment on "A Cluster of Three Cases of Hantavirus Pulmonary Syndrome among Canadian Military Personnel". 61
28096821 2016
87
[Hantavirus pulmonary syndrome in Buenos Aires, 2009-2014]. 61
26826986 2016
88
Landscape, Environmental and Social Predictors of Hantavirus Risk in São Paulo, Brazil. 61
27780250 2016
89
Andes Hantavirus-Infection of a 3D Human Lung Tissue Model Reveals a Late Peak in Progeny Virus Production Followed by Increased Levels of Proinflammatory Cytokines and VEGF-A. 61
26907493 2016
90
Endocytic Pathways Used by Andes Virus to Enter Primary Human Lung Endothelial Cells. 61
27780263 2016
91
Detection of different South American hantaviruses. 61
26220480 2015
92
Viral load of patients with hantavirus pulmonary syndrome in Argentina. 61
26087934 2015
93
[Importation of rare but life-threatening and highly contagious diseases. Current situation and outlook]. 61
26391557 2015
94
Rodent-borne infectious disease outbreaks after flooding disasters: Epidemiology, management, and prevention. 61
26537701 2015
95
Preferential host switching and its relation with Hantavirus diversification in South America. 61
26048884 2015
96
Daily Movements and Microhabitat Selection of Hantavirus Reservoirs and Other Sigmodontinae Rodent Species that Inhabit a Protected Natural Area of Argentina. 61
26063039 2015
97
Diagnosis of hantavirus infection in humans. 61
26091780 2015
98
TRAINING PROGRAM FOR NURSING STAFF REGARDING VIRAL HEMORRHAGIC FEVERS IN A MILITARY HOSPITAL. 61
26485844 2015
99
Toward a Mechanistic Understanding of Environmentally Forced Zoonotic Disease Emergence: Sin Nombre Hantavirus. 61
26955081 2015
100
Hantavirus pulmonary syndrome in Canada: An overview of clinical features, diagnostics, epidemiology and prevention. 61
29769944 2015
101
Phosphorylation of the nucleocapsid protein of Hantaan virus by casein kinase II. 61
25935306 2015
102
Hantavirus pulmonary syndrome, Southern Chile, 1995-2012. 61
25816116 2015
103
Serological evidence of hantavirus infection in apparently healthy people from rural and slum communities in southern Chile. 61
25912713 2015
104
Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure. 61
26046641 2015
105
Multiplex Analysis of Serum Cytokines in Humans with Hantavirus Pulmonary Syndrome. 61
26379668 2015
106
Birth and pathogenesis of rogue respiratory viruses. 61
25423349 2015
107
Rodent-borne infectious disease outbreaks after flooding disasters: Epidemiology, management, and prevention. 61
26663308 2015
108
NK cell activation in human hantavirus infection explained by virus-induced IL-15/IL15Rα expression. 61
25412359 2014
109
DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. 61
25429055 2014
110
Who wants to be a surgeon? Patterns of medical student career choice. 61
25399042 2014
111
Pneumonitis in Syrian golden hamsters (Mesocricetus auratus) infected with Rio Mamoré virus (family Bunyaviridae, genus Hantavirus). 61
25064267 2014
112
Regional variations and time trends of hantavirus pulmonary syndrome in Brazil. 61
24398337 2014
113
Rio Mamoré virus and hantavirus pulmonary syndrome, Brazil. 61
25152089 2014
114
Recognition and management of rodent-borne infectious disease outbreaks after heavy rainfall and flooding. 61
25369218 2014
115
Epidemiology of Hantavirus infections in humans: a comprehensive, global overview. 61
23607444 2014
116
Antigenic properties of N protein of hantavirus. 61
25123683 2014
117
Serological diagnosis of hantavirus pulmonary syndrome in a febrile patient in Colombia. 61
24970702 2014
118
Population ecology of hantavirus rodent hosts in southern Brazil. 61
24935954 2014
119
Serological diagnosis with recombinant N antigen for hantavirus infection. 61
24487183 2014
120
Hemorrhagic Fever with Renal Syndrome in the New, and Hantavirus Pulmonary Syndrome in the Old World: paradi(se)gm lost or regained? 61
24440318 2014
121
Discovery of hantaviruses in bats and insectivores and the evolution of the genus Hantavirus. 61
24509342 2014
122
Maripa hantavirus in French Guiana: phylogenetic position and predicted spatial distribution of rodent hosts. 61
24752689 2014
123
Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques. 61
24778254 2014
124
Development of an immunochromatography strip test based on truncated nucleocapsid antigens of three representative hantaviruses. 61
24885901 2014
125
Modeling to predict cases of hantavirus pulmonary syndrome in Chile. 61
24763320 2014
126
Hantavirus pulmonary syndrome in an Israeli man returning from South America. 61
24834767 2014
127
Hantavirus reservoirs: current status with an emphasis on data from Brazil. 61
24784571 2014
128
Ecological study of hantavirus infection in wild rodents in an endemic area in Brazil. 61
24291677 2014
129
Hantavirus infections among overnight visitors to Yosemite National Park, California, USA, 2012. 61
24565589 2014
130
Twenty years of hantavirus pulmonary syndrome in Brazil: a review of epidemiological and clinical aspects. 61
24518622 2014
131
CDC Grand Rounds: discovering new diseases via enhanced partnership between public health and pathology experts. 61
24522095 2014
132
An innate immunity-regulating virulence determinant is uniquely encoded by the Andes virus nucleocapsid protein. 61
24549848 2014
133
Hantavirus Public Health outreach effectiveness in three populations: an overview of northwestern New Mexico, Los Santos Panama, and Region IX Chile. 61
24584027 2014
134
Estimating hantavirus risk in southern Argentina: a GIS-based approach combining human cases and host distribution. 61
24424500 2014
135
Small interfering RNA inhibition of Andes virus replication. 61
24924189 2014
136
[Conditions for the transmission of Hantavirus in Rio Negro, Argentina]. 61
25347899 2014
137
A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates. 61
24867065 2014
138
[Prognostic factors in hantavirus infections]. 61
24506730 2014
139
A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus. 61
24198421 2014
140
Novel camelid antibody fragments targeting recombinant nucleoprotein of Araucaria hantavirus: a prototype for an early diagnosis of Hantavirus Pulmonary Syndrome. 61
25243411 2014
141
Effectiveness of the ribavirin in treatment of hantavirus infections in the Americas and Eurasia: a meta-analysis. 61
25674609 2014
142
Hypoxia induces permeability and giant cell responses of Andes virus-infected pulmonary endothelial cells by activating the mTOR-S6K signaling pathway. 61
24067973 2013
143
Twenty-year summary of surveillance for human hantavirus infections, United States. 61
24274585 2013
144
Hantavirus pulmonary syndrome outbreak, Brazil, December 2009-January 2010. 61
24207006 2013
145
Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to Andes virus. 61
24217424 2013
146
Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. 61
23856782 2013
147
Another case of "European hantavirus pulmonary syndrome" with severe lung, prior to kidney, involvement, and diagnosed by viral inclusions in lung macrophages. 61
23670277 2013
148
Rapid, whole blood diagnostic test for detecting anti-hantavirus antibody in rats. 61
23684845 2013
149
Cardiopulmonary involvement in Puumala hantavirus infection. 61
24160911 2013
150
A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). 61
23892100 2013
151
Role of vascular and lymphatic endothelial cells in hantavirus pulmonary syndrome suggests targeted therapeutic approaches. 61
24024573 2013
152
Hantavirus fever without pulmonary syndrome in Panama. 61
23836565 2013
153
The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome. 61
23841977 2013
154
Slit2-Robo4 receptor responses inhibit ANDV directed permeability of human lung microvascular endothelial cells. 61
23702092 2013
155
First evidence of asymptomatic infection related to the Araucaria (Juquitiba-like) hantavirus. 61
23917360 2013
156
Human exposure to particulate matter potentially contaminated with sin nombre virus. 61
23532351 2013
157
Hamster-adapted Sin Nombre virus causes disseminated infection and efficiently replicates in pulmonary endothelial cells without signs of disease. 61
23388711 2013
158
Hantavirus-infection confers resistance to cytotoxic lymphocyte-mediated apoptosis. 61
23555267 2013
159
Endothelial cell permeability during hantavirus infection involves factor XII-dependent increased activation of the kallikrein-kinin system. 61
23874198 2013
160
Host mTORC1 signaling regulates andes virus replication. 61
23135723 2013
161
Diversity and distribution of hantaviruses in South America. 61
23055565 2012
162
Hantavirus infections for the clinician: from case presentation to diagnosis and treatment. 61
22553984 2012
163
Development of a minigenome system for Andes virus, a New World hantavirus. 61
22821183 2012
164
Hantavirus pulmonary syndrome in visitors to a national park--Yosemite Valley, California, 2012. 61
23169317 2012
165
Outbreak news. Hantavirus pulmonary syndrome, Yosemite National Park, United States of America. 61
22977952 2012
166
The Syrian hamster model of hantavirus pulmonary syndrome. 61
22705798 2012
167
Hantavirus infection prevalence in wild rodents and human anti-hantavirus serological profiles from different geographic areas of South Brazil. 61
22855773 2012
168
Andes virus infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and vascular endothelial growth factor C sensitive. 61
22696643 2012
169
[Hantavirus pulmonary syndrome (Rio Mamore virus) in the Peruvian Amazon region]. 61
23085803 2012
170
Dysregulation of the β3 integrin-VEGFR2 complex in Hantaan virus-directed hyperpermeability upon treatment with VEGF. 61
22407444 2012
171
Hemorrhagic fever with renal syndrome and coexisting hantavirus pulmonary syndrome. 61
26889418 2012
172
Molecular epidemiology of Laguna Negra virus, Mato Grosso State, Brazil. 61
22607717 2012
173
Sin Nombre hantavirus decreases survival of male deer mice. 61
22218940 2012
174
Complete genome sequence of a novel hantavirus variant of Rio Mamoré virus, Maripa virus, from French Guiana. 61
22492924 2012
175
Hantavirus pulmonary syndrome clinical findings: evaluating a surveillance case definition. 61
22214273 2012
176
Hantavirus pulmonary syndrome: prognostic factors for death in reported cases in Brazil. 61
22475044 2012
177
Geographic distribution of hantaviruses associated with neotomine and sigmodontine rodents, Mexico. 61
22469569 2012
178
[Oligoryzomys longicaudatus characteristics' associated with the presence of Andes virus (Hantavirus)]. 61
22689036 2012
179
Prediction of Peromyscus maniculatus (deer mouse) population dynamics in Montana, USA, using satellite-driven vegetation productivity and weather data. 61
22493110 2012
180
Genetic diversity of hantaviruses in Mexico: identification of three novel hantaviruses from Neotominae rodents. 61
22138671 2012
181
Transmission ecology of Sin Nombre hantavirus in naturally infected North American deermouse populations in outdoor enclosures. 61
23110096 2012
182
[Hantapulmonary syndrome]. 61
22442980 2012
183
Induction of protective immunity in a Syrian hamster model against a cytopathogenic strain of Andes virus. 61
22095538 2012
184
Hantavirus pulmonary syndrome in Santa Cruz, Bolivia: outbreak investigation and antibody prevalence study. 61
23094116 2012
185
DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS). 61
22558299 2012
186
Elevated VEGF Levels in Pulmonary Edema Fluid and PBMCs from Patients with Acute Hantavirus Pulmonary Syndrome. 61
22956954 2012
187
The Role of the Endothelium in HPS Pathogenesis and Potential Therapeutic Approaches. 61
22811711 2012
188
Severe pulmonary involvement in a case attributed to domestically acquired Seoul hantavirus in the United States. 61
22042876 2012
189
Second external quality assurance study for the serological diagnosis of hantaviruses in Europe. 61
22509420 2012
190
Infection of Hantaan virus strain AA57 leading to pulmonary disease in laboratory mice. 61
22044619 2012
191
Hantavirus pulmonary syndrome. 61
21945215 2011
192
Epidemic Intelligence Service investigations of respiratory illness, 1946-2005. 61
22135392 2011
193
Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus. 61
22194683 2011
194
Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. 61
21917979 2011
195
Imaging of hemorrhagic fever with renal syndrome: a potential bioterrorism agent of military significance. 61
22165665 2011
196
Cytokine expression during early and late phase of acute Puumala hantavirus infection. 61
22085404 2011
197
Dynamics of hantavirus infection in Peromyscus leucopus of central Pennsylvania. 61
21756028 2011
198
T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome. 61
21775442 2011
199
Incidence rate for hantavirus infections without pulmonary syndrome, Panama. 61
22000376 2011
200
Presence of activated airway T lymphocytes in human puumala hantavirus disease. 61
21436245 2011
201
Modeling potential distribution of Oligoryzomys longicaudatus, the Andes virus (Genus: Hantavirus) reservoir, in Argentina. 61
22130568 2011
202
Hantavirus pulmonary syndrome, United States, 1993-2009. 61
21762572 2011
203
Hantavirus pulmonary syndrome: need for prevention and early diagnosis. 61
21886056 2011
204
A novel hantavirus detected in Yunnan red-backed vole (Eothenomys miletus) in China. 61
21402592 2011
205
Notes from the field: hantavirus pulmonary syndrome --- Maine, April 2011. 61
21681176 2011
206
Seroepidemiological survey of hantavirus infection in healthy people in Vallès Occidental, Barcelona. 61
21417923 2011
207
Time to revise the paradigm of hantavirus syndromes? Hantavirus pulmonary syndrome caused by European hantavirus. 61
21234633 2011
208
Biogeographic and ecological regulation of disease: prevalence of Sin Nombre virus in island mice is related to island area, precipitation, and predator richness. 61
21508614 2011
209
The relative abundance of deer mice with antibody to Sin Nombre virus corresponds to the occurrence of hantavirus pulmonary syndrome in nearby humans. 61
20954865 2011
210
Hantavirus pulmonary syndrome: when should you consider this diagnosis? 61
21670936 2011
211
Hantavirus pulmonary syndrome: encephalitis caused by virus Andes. 61
21240581 2011
212
VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. 61
21177802 2011
213
Genetic characterization of hantaviruses associated with sigmodontine rodents in an endemic area for hantavirus pulmonary syndrome in southern Brazil. 61
21138380 2011
214
Serosurvey of hantavirus infection in humans in the border region between Brazil and Argentina. 61
21468477 2011
215
Rodent community structure and Andes virus infection in sylvan and peridomestic habitats in northwestern Patagonia, Argentina. 61
21332352 2011
216
In vitro and in vivo activity of ribavirin against Andes virus infection. 61
21853152 2011
217
Hantavirus pulmonary syndrome in Argentina, 1995-2008. 61
21122213 2010
218
Hantaviruses and hantavirus pulmonary syndrome, Maranhao, Brazil. 61
21122229 2010
219
Andes virus regulation of cellular microRNAs contributes to hantavirus-induced endothelial cell permeability. 61
20844033 2010
220
Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. 61
20810734 2010
221
Hantavirus pulmonary syndrome coexistent with Dengue. 61
21302604 2010
222
Convalescent pulmonary dysfunction following hantavirus pulmonary syndrome in Panama and the United States. 61
20524006 2010
223
Early diagnosis of hantavirus infection by family doctors can reduce inappropriate antibiotic use and hospitalization. 61
20642397 2010
224
Circulation of hantaviruses in the influence area of the Cuiabá-Santarém Highway. 61
20835614 2010
225
Sin Nombre virus-specific immunoglobulin M and G kinetics in hantavirus pulmonary syndrome and